-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Cerus (NASDAQ:CERS) Shares Gap Up to $3.83
Cerus (NASDAQ:CERS) Shares Gap Up to $3.83
Cerus Co. (NASDAQ:CERS – Get Rating)'s share price gapped up prior to trading on Wednesday . The stock had previously closed at $3.83, but opened at $3.98. Cerus shares last traded at $3.93, with a volume of 6,873 shares changing hands.
Analyst Upgrades and Downgrades
CERS has been the subject of a number of research analyst reports. StockNews.com began coverage on shares of Cerus in a report on Wednesday, October 12th. They issued a "hold" rating for the company. BTIG Research dropped their target price on shares of Cerus to $6.00 in a report on Tuesday, November 15th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Cerus in a research note on Monday, December 5th.
Get Cerus alerts:Cerus Trading Down 0.7 %
The company has a debt-to-equity ratio of 0.37, a current ratio of 1.73 and a quick ratio of 1.44. The business has a 50-day moving average price of $3.82 and a two-hundred day moving average price of $4.41. The firm has a market cap of $727.43 million, a PE ratio of -18.64 and a beta of 1.08.
Cerus (NASDAQ:CERS – Get Rating) last posted its earnings results on Thursday, November 3rd. The biotechnology company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). Cerus had a negative net margin of 24.24% and a negative return on equity of 48.32%. The firm had revenue of $39.57 million during the quarter, compared to the consensus estimate of $39.00 million. Analysts forecast that Cerus Co. will post -0.21 EPS for the current year.Insider Activity at Cerus
In other news, Director Daniel N. Swisher, Jr. sold 12,500 shares of the business's stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $3.91, for a total value of $48,875.00. Following the completion of the transaction, the director now directly owns 113,808 shares of the company's stock, valued at $444,989.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 7.33% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Cerus
Institutional investors have recently modified their holdings of the company. MQS Management LLC purchased a new stake in Cerus in the 3rd quarter worth approximately $159,000. Bank of New York Mellon Corp grew its position in shares of Cerus by 9.4% in the third quarter. Bank of New York Mellon Corp now owns 631,907 shares of the biotechnology company's stock valued at $2,275,000 after purchasing an additional 54,494 shares during the period. Robeco Institutional Asset Management B.V. acquired a new position in Cerus in the third quarter valued at $87,000. Capital Impact Advisors LLC acquired a new position in Cerus in the third quarter valued at $49,000. Finally, Tamarack Advisers LP lifted its position in Cerus by 21.3% during the third quarter. Tamarack Advisers LP now owns 2,425,000 shares of the biotechnology company's stock worth $8,730,000 after buying an additional 425,000 shares during the period. Institutional investors and hedge funds own 82.47% of the company's stock.
Cerus Company Profile
(Get Rating)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Featured Articles
- Get a free copy of the StockNews.com research report on Cerus (CERS)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.
Cerus Co. (NASDAQ:CERS – Get Rating)'s share price gapped up prior to trading on Wednesday . The stock had previously closed at $3.83, but opened at $3.98. Cerus shares last traded at $3.93, with a volume of 6,873 shares changing hands.
賽樂斯股份有限公司(納斯達克代碼:CERS-GET Rating)週三盤前股價跳水,此前收盤價為3.83美元,開盤報3.98美元。賽樂斯股票最新報3.93美元,總成交量為6,873股。
Analyst Upgrades and Downgrades
分析師升級和下調評級
CERS has been the subject of a number of research analyst reports. StockNews.com began coverage on shares of Cerus in a report on Wednesday, October 12th. They issued a "hold" rating for the company. BTIG Research dropped their target price on shares of Cerus to $6.00 in a report on Tuesday, November 15th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Cerus in a research note on Monday, December 5th.
CER已成為多份研究分析家報告的主題。StockNews.com在10月12日星期三的一份報告中開始報道Cerus的股票。他們對該公司的評級為“持有”。BTIG Research在11月15日星期二的一份報告中將Cerus的股票目標價下調至6.00美元。最後,康託·菲茨傑拉德在12月5日星期一的一份研究報告中重新發布了對Cerus股票的“增持”評級。
Cerus Trading Down 0.7 %
Cerus交易下跌0.7%
The company has a debt-to-equity ratio of 0.37, a current ratio of 1.73 and a quick ratio of 1.44. The business has a 50-day moving average price of $3.82 and a two-hundred day moving average price of $4.41. The firm has a market cap of $727.43 million, a PE ratio of -18.64 and a beta of 1.08.
該公司的債務權益比為0.37,流動比率為1.73,速動比率為1.44。該業務的50日移動均線價格為3.82美元,200日移動均線價格為4.41美元。該公司市值為7.2743億美元,本益比為-18.64倍,貝塔係數為1.08。
Insider Activity at Cerus
Cerus的內幕活動
In other news, Director Daniel N. Swisher, Jr. sold 12,500 shares of the business's stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $3.91, for a total value of $48,875.00. Following the completion of the transaction, the director now directly owns 113,808 shares of the company's stock, valued at $444,989.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 7.33% of the stock is owned by corporate insiders.
其他新聞,董事小Daniel·N·斯威舍在11月10日星期四的一次交易中出售了12,500股該公司的股票。這只股票的平均售價為3.91美元,總價值為48,875.00美元。交易完成後,董事現在直接擁有113,808股該公司股票,價值444,989.28美元。這筆交易是在提交給美國證券交易委員會的一份法律檔案中披露的,該檔案可通過此超鏈接。7.33%的股份由企業內部人士持有。
Hedge Funds Weigh In On Cerus
對沖基金看好Cerus
Institutional investors have recently modified their holdings of the company. MQS Management LLC purchased a new stake in Cerus in the 3rd quarter worth approximately $159,000. Bank of New York Mellon Corp grew its position in shares of Cerus by 9.4% in the third quarter. Bank of New York Mellon Corp now owns 631,907 shares of the biotechnology company's stock valued at $2,275,000 after purchasing an additional 54,494 shares during the period. Robeco Institutional Asset Management B.V. acquired a new position in Cerus in the third quarter valued at $87,000. Capital Impact Advisors LLC acquired a new position in Cerus in the third quarter valued at $49,000. Finally, Tamarack Advisers LP lifted its position in Cerus by 21.3% during the third quarter. Tamarack Advisers LP now owns 2,425,000 shares of the biotechnology company's stock worth $8,730,000 after buying an additional 425,000 shares during the period. Institutional investors and hedge funds own 82.47% of the company's stock.
機構投資者最近調整了對該公司的持股。MQS Management LLC在第三季度購買了Cerus的新股份,價值約15.9萬美元。紐約梅隆銀行(Bank Of New York Mellon Corp)第三季度持有的Cerus股票頭寸增加了9.4%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有這家生物技術公司631,907股股票,價值2,275,000美元,在此期間又購買了54,494股。Robeco機構資產管理公司在第三季度收購了Cerus的一個新頭寸,價值8.7萬美元。Capital Impact Advisors LLC在第三季度收購了Cerus的一個新頭寸,價值49,000美元。最後,Tamarack Advisers LP在第三季度將其在Cerus的頭寸提高了21.3%。Tamarack Advisers LP現在擁有2,425,000股這家生物技術公司的股票,價值8,730,000美元,在此期間又購買了425,000股。機構投資者和對沖基金持有該公司82.47%的股票。
Cerus Company Profile
Cerus公司簡介
(Get Rating)
(獲取評級)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Cerus公司是一家生物醫藥產品公司。該公司專注於開發攔截血液系統並將其商業化,以增強血液安全。其攔截血液系統,這是一項控制生物複製的專利技術,旨在減少用於輸血的捐獻血液成分中的血源性病原體。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Cerus (CERS)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- 免費獲取StockNews.com關於Cerus的研究報告(CERS)
- 你買下Palantir的決定可能只是個時間問題
- 卡特彼勒和迪爾準備在2023年重整旗鼓嗎?
- 馬倫汽車公司在i-Go登陸歐洲之際受到震動
- 2023年,太陽會照耀這3只大盤太陽能股嗎?
- Lucid Motors面臨的現實可能會給看漲的看法蒙上陰影
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Cerus Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cerus和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧